SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV)
SKBI
SKBI was delisted on the 18th of December, 2015.
5 hedge funds and large institutions have $795K invested in SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) in 2013 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.
126% more capital invested
Capital invested by funds: $351K → $795K (+$444K)
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
25% more funds holding
Funds holding: 4 → 5 (+1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$108K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Corsair Capital Management
New York
|
-$444K |
| 2 |
U
UBS
Zurich,
Switzerland
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CCM
1
Corsair Capital Management
New York
| $358K | -$444K | -179,536 | -75% |
|
|
2
Royal Bank of Canada
Toronto,
Ontario, Canada
| $254K | +$108K | +43,641 | New |
|
3
California Public Employees Retirement System
Sacramento,
California
| $93K | – | – | – |
|
4
Mitsubishi UFJ Asset Management
Tokyo,
Japan
| $87K | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $3K | +$1.12K | +454 | New |
|
|
U
6
UBS
Zurich,
Switzerland
| – | -$6K | -4,405 | Closed |
|
SKBI Hedge Fund Activity: Q3 2013 in Review
5 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) (SKBI) for Q3 2013, worth a combined $795K — up 126% from $351K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new SKBI positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Royal Bank of Canada, opening a new position worth an estimated $108K. The largest seller was Corsair Capital Management, cutting an estimated $444K.
- 5 institutional investors held SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) (SKBI) as of Q3 2013, up from 4 in Q2 2013.
- Funds reported $795K of SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) stock for Q3 2013, up 126% quarter-over-quarter.
- 2 funds opened new SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) positions in Q3 2013 and 1 closed out, a net change of +1 holder.
- The largest SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) buyer in Q3 2013 was Royal Bank of Canada, an estimated $108K added.
- The largest SKYSTAR BIO-PHARMACEUTICAL CO COM PAR $.001 (NV) seller in Q3 2013 was Corsair Capital Management, an estimated $444K sold.
Based on aggregated 13F filings for Q3 2013.